Abstrakt

Przypisy

• 1. Ahmad S.: L-carnitine in dialysis patients. Semin. Dial., 2001;14: 209-217
  Google Scholar
• 2. Asbrink E., Hovmark A.: Comments on the course and classificationof Lyme borreliosis. Scand. J. Infect. Dis. Suppl., 1991; 77: 41-43
  Google Scholar
• 3. Bennet R., Lindgren V., Zweygberg Wirgart B.: Borrelia antibodiesin children evaluated for Lyme neuroborreliosis. Infection, 2008;36: 463-466
  Google Scholar
• 4. Calvani M., Benatti P., Mancinelli A., D’Iddio S., Giordano V., KoverechA., Amato A., Brass E.P.: Carnitine replacement in end-stagerenal disease and hemodialysis. Ann. N.Y. Acad. Sci., 2004; 1033: 52-66
  Google Scholar
• 5. Cederblad G., Harper P., Lindgren K.: Spectrophotometry of carnitinein biological fluids and tissue with a Cobas Bio centrifugalanalyzer. Clin. Chem., 1986; 32: 342-346
  Google Scholar
• 6. Coyle P.K., Schutzer S.E.: Neurologic aspects of Lyme disease.Med. Clin. North Am., 2002; 86: 261-284
  Google Scholar
• 7. Estrada-Peña A., de la Fuente J.: The ecology of ticks and epidemiologyof tick-borne viral diseases. Antiviral Res., 2014; 108: 104-128 8 Famularo G., De Simone C., Trinchieri V., Mosca L.: Carnitines andits congeners: a metabolic pathway to the regulation of immune responseand inflammation. Ann. N.Y. Acad. Sci., 2004; 1033: 132-138
  Google Scholar
• 8. (IL-8) in Lyme borreliosis. Infection, 2004; 32: 350-355
  Google Scholar
• 9. Flanagan J.L., Simmons P.A., Vehige J., Willcox M.D., Garrett Q.:Role of carnitine in disease. Nutr. Metab., 2010; 7: 30
  Google Scholar
• 10. Grygorczuk S., Pancewicz S., Zajkowska J., Kondrusik M.,Świerzbińska R., Hermanowska-Szpakowicz T.: Concentrations ofmacrophage inflammatory proteins MIP-1α and MIP-1β and interleukin
  Google Scholar
• 11. Indiveri C., Pochini L., Oppedisano F., Tonazzi A.: The carnitinetransporter network: interactions with drugs. Curr. Chem. Biol.,2010; 4: 108-123
  Google Scholar
• 12. Kępka A., Kuroczycka-Saniutycz E., Chojnowska S., FiłonowiczR., Korzeniecka-Kozerska A., Wasilewska A.: Urine L-carnitine excretionin hypertensive adolescents. Ir. J. Med. Sci., 2015; 184: 219-225
  Google Scholar
• 13. Kępka, A., Minarowska, A., Minarowski, Ł., Waszkiewicz N., ChojnowskaS., Trochimowicz L., Zwierz K., Chyczewska E., Szajda S.D.:Serum and urinary carnitine in children with cystic fibrosis. Prog.Health Sci., 2013; 3: 13-18
  Google Scholar
• 14. Madiraju P., Pande S.V., Prentki M., Madiraju S.R.: Mitochondrialacetylcarnitine provides acetyl groups for nuclear histone acetylation.Epigenetics, 2009; 4: 399-403
  Google Scholar
• 15. Mels C.M., Schutte A.E., Erasmus E., Huisman H.W., Schutte R.,Fourie C.M., Kruger R., Van Rooyen J.M., Smith W., Malan N.T., MalanL.: L-carnitine and long-chain acylcarnitines are positively correlatedwith ambulatory blood pressure in humans: the SABPA study.Lipids, 2013; 48: 63-73
  Google Scholar
• 16. Moniuszko A., Dunaj J., Święcicka I., Zambrowski G., Chmielewska-Badora J., Zukiewicz-Sobczak W., Zajkowska J., Czupryna P., KondrusikM., Grygorczuk S., Swierzbinska R., Pancewicz S.: Co-infectionswith Borrelia species, Anaplasma phagocytophilum and Babesiaspp. in patients with tick-borne encephalitis. Eur. J. Clin. Microbiol.Infect. Dis., 2014; 33: 1835-1841
  Google Scholar
• 17. Ogrinc K., Lotrič-Furlan S., Maraspin V., Lusa L., Cerar T., Ružič–Sabljič E., Strle F.: Suspected early Lyme neuroborreliosis in patientswith erythema migrans. Clin. Infect. Dis., 2013; 57: 501-509
  Google Scholar
• 18. Ribas G.S., Vargas C.R., Wajner M.: L-carnitine supplementationas a potential antioxidant therapy for inherited neurometabolic disorders.Gene, 2014; 533: 469-476
  Google Scholar
• 19. Schmidt-Sommerfeld E., Werner D., Penn D.: Carnitine plasmaconcentrations in 353 metabolically healthy children. Eur. J. Pediatr.,1988; 147: 356-360
  Google Scholar
• 20. Wormser G.P., Halperin J.J.: Toward a better understanding ofEuropean Lyme neuroborreliosis. Clin. Infect. Dis., 2013; 57: 510-512
  Google Scholar

Pełna treść artykułu